Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare reimbursement tables, patient-day metrics, and hospice turnover data are scattered across hundreds of pages of Enhabit’s disclosures. If parsing those figures in the latest Enhabit annual report 10-K simplified seems daunting, you’re not alone. Healthcare accounting rules create footnotes that read like another language. Stock Titan’s AI turns that language into clear insights, making Enhabit SEC filings explained simply. Whether you’re scanning for regulatory risks or auditing segment margins, our platform surfaces what matters before you wade through dense jargon.
Need the next Enhabit quarterly earnings report 10-Q filing or an alert on Enhabit Form 4 insider transactions real-time? Our engine pulls every document the moment it hits EDGAR and delivers AI-powered summaries in seconds. Investors searching for:
- Enhabit insider trading Form 4 transactions
- Enhabit proxy statement executive compensation
- Enhabit 8-K material events explained
- Enhabit earnings report filing analysis
receive a single dashboard that connects each form to real questions: What did executives buy, how did home-health margins shift, and did CMS rule changes impact revenue guidance?
Understanding Enhabit SEC documents with AI also means context. Our tools highlight hospice census trends, regional payor mixes, and quality-of-care metrics buried deep in footnotes. Curious about Enhabit executive stock transactions Form 4 ahead of a rate update? Want a red-lined comparison that shows how the new filing differs from last year? Stock Titan provides real-time updates, side-by-side comparisons, and plain-English explanations, so you can decide faster, act sooner, and focus on the fundamentals driving home-health performance.
Enhabit, Inc. (EHAB) – Form 4 Insider Transaction
Director Charles M. Elson reported the acquisition of 2,579 common-stock deferred stock units on 10 Jul 2025 under the company’s Deferred Director Compensation Plan. The units were valued at $7.27 per share, representing roughly $18.8 thousand in equity received in lieu of a cash retainer. Following the award, Elson’s total direct beneficial ownership rises to 75,073 shares.
- Transaction code “A” denotes an award or grant, not an open-market purchase.
- The incremental increase is about 3.6 % versus Elson’s prior stake of roughly 72,494 shares.
- No derivative securities were involved in this filing.
The filing signals routine compensation rather than a discretionary purchase, so market impact is expected to be limited. However, growing insider ownership can be interpreted as modestly positive for alignment with shareholder interests.
FAQ
What is the current stock price of Enhabit (EHAB)?
What is the market cap of Enhabit (EHAB)?
